Search clinical trials for: Serotonin 5-HT1 Receptor Agonists

Total 7375 results

Pfizer

Completed

A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack

Migraine

United States
Teva Pharmaceuticals USA

Completed

Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions

Healthy

Canada
Chimei Medical Center

Completed

Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression

Major Depressive Disorder

Taiwan
Zogenix, Inc.

Completed

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

Healthy
Danish Headache Center

Completed

PACAP38 Induced Headache and Rosacea-like Symptoms in Patients With Rosacea

Rosacea

Denmark
Dr. Reddy's Laboratories Limited

Completed

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

Rapidly Escalating Migraine

United States
AstraZeneca

Completed

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents

Migraine
AstraZeneca

Completed

Efficacy and Tolerability of Zolmitriptan Nasal Spray

Migraine
Washington University School of Medicine
Takeda; Queen's University

Completed

Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training (BBS)

Age-related Cognitive Decline

United States
H. Lundbeck A/S

Completed

A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

Healthy Male Adults

Japan
Central South University

Recruiting

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Bipolar Disorder | Major Depressive Disorder

China
Takeda

Completed

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Major Depressive Disorder

Japan
Centre Hospitalier St Anne

Not yet recruiting

Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation (STRATIDEP)

Major Depressive Disorder

France
Fundación Pública Andaluza para la gestión de la...

Recruiting

Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia (CAVES)

Negative Symptoms With Primary Psychotic Disorder | Cognitive Impairment With Primary Psychotic Disorder

Spain
Seasons Biotechnology (Taizhou) Co., Ltd.

Completed

Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Major Depressive Disorder (MDD)

India
Sir Run Run Shaw Hospital
Huazhong University of Science and Technology; Shenzhen Mental Health Center

Unknown

MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users

Depression | Cognitive Impairment | Relapse
H. Lundbeck A/S
Takeda

Completed

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

Depressive Disorder, Major

Finland, Estonia
Daiichi Sankyo, Inc.

Completed

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

Parkinson's Disease

United States, Guatemala, Romania
Daiichi Sankyo, Inc.

Terminated

Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

Stroke

United States, Israel, Poland, Spain, Belgium, Germany, South Africa
Clinvest
Merck Sharp & Dohme LLC

Completed

Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine

Headache, Migraine

United States
Otsuka Beijing Research Institute
Zhejiang Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia

Schizophrenia

China
Teva Pharmaceuticals USA

Completed

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Forest Laboratories

Completed

A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-23)

Major Depressive Disorder

United States, Canada
NuPathe Inc.

Completed

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Acute Migraine
European Institute for Evidence Based Osteopathic...

Completed

Clinical Effectiveness of Osteopathic Manipulative Treatment in Chronic Migraine

Migraine

Italy
University of Calgary

Completed

Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study (IEMPru)

Dysphagia | Ineffective Esophageal Motility

Canada
Shanghai Mental Health Center
Shanghai Jiao Tong University School of Medicine

Not yet recruiting

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

Schizophrenia

China
Deborah Yurgelun-Todd
Otsuka America Pharmaceutical

Completed

Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism

Schizophrenia

United States
Otsuka Beijing Research Institute

Completed

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

Tourette Syndrome

China
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Bipolar Disorder Mania

Italy, Poland, Russian Federation, Turkey, South Africa, Austria, Hungary, France, Spain, Czech Republic, Germany, Greece, Romania
Movetis

Completed

Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation

Chronic Constipation

United States
Zosano Pharma Corporation

Completed

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

Cluster Headache

United States
Eli Lilly and Company

Terminated

Study in Participants With Acute Migraines Headaches

Migraine Headache

United States
Centre for Addiction and Mental Health
Janssen Inc.

Recruiting

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

Schizophrenia | Schizophrenia Relapse

Canada
University of California, Los Angeles
Alkermes, Inc.

Terminated

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (APPRAISE)

Schizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive Type

United States
Future University in Egypt

Completed

Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition

Healthy Subjects

Egypt
Alkermes, Inc.

Completed

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Schizophrenia

United States
University of British Columbia
Bristol-Myers Squibb

Completed

Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (CALM)

Psychotic Disorders | Bipolar Disorder | Metabolic Syndrome X

Canada
UMC Utrecht

Completed

European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)

Schizophrenia

Netherlands, Norway, Austria, Belgium, Bulgaria, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Romania, Spain, United Kingdom
Northwell Health

Terminated

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

High Risk MC4R Genotype | Low Risk MC4R Genotype | One Week or Less Antipsychotic Lifetime Exposure

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness (SMART-M)

Bipolar Disorder

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness (SMART-A)

Bipolar Disorder

Korea, Republic of
Universitaire Ziekenhuizen KU Leuven

Completed

Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

Migraine

Belgium
Alder Biopharmaceuticals, Inc.

Completed

Safety Tolerability and Pharmacokinetics of ALD403

Migraine Disorders

Australia
Janssen Pharmaceutica

Withdrawn

A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation

Chronic Constipation

Philippines
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

Migraine Disorders

Japan
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia

3

Subscribe